Tower Research Capital (TRC)’s Clearside Biomedical CLSD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-54
| Closed | -$648 | – | 5262 |
|
|
2025
Q2 | $648 | Sell |
54
-274
| -84% | -$3.4K | ﹤0.01% | 4971 |
|
|
2025
Q1 | $4.51K | Sell |
328
-73
| -18% | -$1.05K | ﹤0.01% | 4246 |
|
|
2024
Q4 | $5.71K | Buy |
401
+199
| +99% | +$3.27K | ﹤0.01% | 4254 |
|
|
2024
Q3 | $3.85K | Sell |
202
-858
| -81% | -$14.6K | ﹤0.01% | 4756 |
|
|
2024
Q2 | $20.7K | Buy |
1,060
+534
| +102% | +$10.3K | ﹤0.01% | 3748 |
|
|
2024
Q1 | $12.1K | Sell |
526
-408
| -44% | -$8.79K | ﹤0.01% | 3513 |
|
|
2023
Q4 | $16.4K | Buy |
934
+212
| +29% | +$3.02K | ﹤0.01% | 3781 |
|
|
2023
Q3 | $9.43K | Buy |
+722
| New | +$10.9K | ﹤0.01% | 4218 |
|
|
2023
Q2 | – | Sell |
-4
| Closed | – | – | 6069 |
|
|
2023
Q1 | $0 | Buy |
+4
| New | +$78 | ﹤0.01% | 5857 |
|
|
2022
Q4 | – | Sell |
-163
| Closed | -$2K | – | 5938 |
|
|
2022
Q3 | $2K | Buy |
163
+118
| +262% | +$2.58K | ﹤0.01% | 5533 |
|
|
2022
Q2 | $1K | Sell |
45
-510
| -92% | -$12.4K | ﹤0.01% | 5751 |
|
|
2022
Q1 | $19K | Sell |
555
-287
| -34% | -$8.59K | ﹤0.01% | 3569 |
|
|
2021
Q4 | $35K | Buy |
842
+646
| +330% | +$41.8K | ﹤0.01% | 3074 |
|
|
2021
Q3 | $18K | Buy |
+196
| New | +$17.3K | ﹤0.01% | 3811 |
|
|
2021
Q2 | – | Sell |
-1,111
| Closed | -$41K | – | 5511 |
|
|
2021
Q1 | $41K | Buy |
1,111
+796
| +253% | +$40K | ﹤0.01% | 3284 |
|
|
2020
Q4 | $13K | Sell |
315
-516
| -62% | -$13.4K | ﹤0.01% | 4134 |
|
|
2020
Q3 | $19K | Buy |
831
+756
| +1,008% | +$19.5K | ﹤0.01% | 3879 |
|
|
2020
Q2 | $2K | Buy |
+75
| New | +$2.21K | ﹤0.01% | 4474 |
|
|
2019
Q3 | – | Sell |
-515
| Closed | -$8K | – | 4128 |
|
|
2019
Q2 | $8K | Buy |
515
+457
| +788% | +$8.15K | ﹤0.01% | 2676 |
|
|
2019
Q1 | $1K | Sell |
58
-261
| -82% | -$5.18K | ﹤0.01% | 3540 |
|
|
2018
Q4 | $5K | Buy |
319
+200
| +168% | +$9.38K | ﹤0.01% | 2885 |
|
|
2018
Q3 | $11K | Sell |
119
-359
| -75% | -$42.7K | ﹤0.01% | 2685 |
|
|
2018
Q2 | $77K | Sell |
478
-334
| -41% | -$56.3K | ﹤0.01% | 1597 |
|
|
2018
Q1 | $130K | Buy |
+812
| New | +$98.9K | 0.01% | 1102 |
|
|
2017
Q4 | – | Sell |
-185
| Closed | -$24K | – | 3566 |
|
|
2017
Q3 | $24K | Buy |
+185
| New | +$22.6K | ﹤0.01% | 2608 |
|
|
2017
Q1 | – | Sell |
-179
| Closed | -$24K | – | 3145 |
|
|
2016
Q4 | $24K | Sell |
179
-442
| -71% | -$111K | ﹤0.01% | 1964 |
|
|
2016
Q3 | $162K | Buy |
621
+588
| +1,782% | +$72K | 0.02% | 584 |
|
|
2016
Q2 | $4K | Buy |
+33
| New | +$3.46K | ﹤0.01% | 3503 |
|
Other funds holding CLSD
CG
AWM
GCP
Tower Research Capital (TRC)'s CLSD Position: Q3 2025 in Review
Tower Research Capital (TRC) sold out of Clearside Biomedical (CLSD) in Q3 2025, closing a stake of 54 shares — an estimated $648 sold.
Tower Research Capital (TRC) first reported a position in CLSD in Q2 2016 and held it in 28 quarters. The position peaked at $162K in Q3 2016. 26 funds tracked by Wall St. Rank hold CLSD as of Q3 2025.
- Tower Research Capital (TRC) reported no remaining Clearside Biomedical position as of Q3 2025 after selling out during the quarter.
- Tower Research Capital (TRC) sold 54 Clearside Biomedical shares in Q3 2025, an estimated $648.
- Tower Research Capital (TRC) first reported a position in Clearside Biomedical in Q2 2016 and held it in 28 quarters.
- Tower Research Capital (TRC)'s Clearside Biomedical position peaked at $162K in Q3 2016.
- 26 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2025.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2025, filed 14 Nov 2025.